Group 1 - The core viewpoint of the articles highlights the increasing interest and investment in China's innovative drug sector, particularly through the Hong Kong Stock Connect Innovative Drug ETF (159570), which has seen significant net inflows over the past days [1][5][7] - The Hong Kong Stock Connect Innovative Drug ETF (159570) has experienced a trading volume exceeding 320 million yuan, with nearly 200 million yuan in net inflows over the past five days, indicating strong market confidence in the innovative drug sector [1][7] - Key component stocks of the ETF have shown mixed performance, with notable gains from China Biologic Products and CSPC Pharmaceutical Group, while some stocks like Wondfo Biotech and Innovent Biologics have seen declines [2][3] Group 2 - The impact of U.S. drug pricing policies on Chinese innovative drugs is complex, with the potential for limited effects on major pharmaceutical companies due to the intricate U.S. healthcare system and pricing mechanisms [4][5] - Chinese innovative drugs are viewed as high-quality assets, with a significant increase in business development (BD) activities expected, driven by the expiration of patents for many drugs by 2028 [5][7] - The value of Chinese innovative drugs is underscored by projected revenue from licensing agreements, with an estimated 5.7 billion USD in upfront payments expected in 2024, representing 20% of global cooperation licensing payments [5][7] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (159570) is characterized by a high concentration in innovative drug companies, with over 68% of its top ten holdings in this sector, showcasing its focus on leading firms [7] - The ETF is noted for its high weight in innovative drugs (84%) and relatively low valuation metrics, making it an attractive option for investors looking to capitalize on the growth of the innovative drug industry [7]

值得关注的是，据Wind数据统计，截至发稿，港股通创新药ETF工银（159217）当前管理费率与托管 费率分别为0.4%、0.07%，其费率在同为跟踪国证港股通指数的产品中最低。 消息面上，多家A股、港股创新药企发布亮眼财报以及在研产品的阶段性突破进展。此外据证券时报， 近期全国多地政府相继出台政策，鼓励医药行业并购重组壮大发展，并提出医药产业基金的相关规划。 在更高层面，国务院国资委党委近日在《民主与法制》周刊发表署名文章中提出，对于生物医药等产业 基础比较薄弱的领域，鼓励国有企业运用并购重组、股权投资、产业基金等多种方式，加快形成产业影 响力。 中信建投证券表示，我国创新药全球竞争力持续增强，NewCo模式成为创新药出海新选择，国家政策 鼓励创新药发展，新技术推动行业快速发展，持续看好创新药行业。 Wind数据显示，截至4月29日收盘，国证港股通创新药指数（987017）近一年涨幅达48.11%，在同类指 数中居首。相关ETF方面，跟踪国证港股通指数的港股通创新药ETF工银（159217）交投活跃。港股通 创新药ETF工银当日成交额达1.54亿元，换手率5.58%，最新规模为27.27亿元。资金流向方面， ...